The shares granted were fully vested upon grant and the Company recognized the grant date fair value of the shares of $56,600 as investor relations expense upon ...
MabVax Therapeutics (MBVX) Investor Presentation - Slideshow · SA TranscriptsFri, Apr. 07, 2017. MabVax Therapeutics Holdings (MBVX) Investor Presentation ...
Missing: relations | Show results with:relations
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports ( ...
Seeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects.
Missing: relations | Show results with:relations
(Nasdaq: MBVX), a clinical-stage oncology drug development company. Under the terms of the agreement, BioNTech has acquired MabVax Therapeutics' lead candidate, ...
Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds (or held) ...
A$0.99
MabVax Therapeutics Holdings (MBVX) Overview. Read detailed company information including current share prices, financial summary, directors, announcements, ...
Missing: relations | Show results with:relations
A$0.99
Currently there is no data available for this company. Intelligent Investor free trial for buy hold sell stock recommendations.
Missing: relations | Show results with:relations
Mar 22, 2018 · The general public holds a substantial 45.12% stake in MBVX, making it a highly popular stock among retail investors. This size of ownership ...
The Investor Relations website contains information about Abivax's business for stockholders, potential investors, and financial analysts.
Missing: mbvx | Show results with:mbvx